BIOMEDE Trial Found No Survival Gain From Targeted Drugs in DIPG
TL;DR: A 2026 randomized phase 2 trial in Nature Medicine found that three targeted drugs added to radiotherapy did not improve overall survival for children with diffuse intrinsic pontine glioma (DIPG), a lethal brainstem tumor, although everolimus caused fewer treatment-stopping side effects. Key Findings 233 randomized patients: BIOMEDE assigned 36 children to erlotinib, 102 to …
